#USA #New York #Levi & Korsinsky #Aardvark Therapeutics #AARD

Aardvark Therapeutics Investors Alerted About Class Action Lawsuit

Introduction
Aardvark Therapeutics, Inc. (NASDAQ: AARD) is currently embroiled in a class action lawsuit that could impact many institutional investors. The lawsuit has gained considerable attention due, in part, to claims that the company misrepresented crucial safety information related to its drug candidate ARD-101. With the lead plaintiff deadline rapidly approaching on October 13, 2026, it’s critical for affected investors to understand their options and rights.

Background of the Case

Levi & Korsinsky, LLP has formally notified institutional investors holding shares of Aardvark Therapeutics that they may want to assess their positions in light of this ongoing litigation. The lawsuit involves claims made by shareholders who acquired shares between February 13, 2025, and May 14, 2026, a period that coincides with the company's IPO and beyond. Investors are concerned following a significant drop in Aardvark's stock price, which has plummeted from an IPO price of $16.00 to around $4.57. This decline represents a staggering loss of about 71.4%, driving interest in the class action.

Allegations Against Aardvark Therapeutics

The core of the lawsuit revolves around allegations that Aardvark therapeutics misrepresented the safety profile of ARD-101. Internal communications and offering documents indicated that the drug was approximately 99% gut-restricted with minimal systemic absorption and no serious adverse side effects. However, the complaint contends that these claims grossly underestimated the drug's safety risks. Following reports of reversible cardiac issues during trials, Aardvark announced in February 2026 a voluntary stop to its Phase 3 HERO trial and received a full clinical hold from the FDA by May 2026.

Investor Considerations

For institutional investors, understanding their legal standing and potential recovery options is vital. Those who purchased AARD shares in the specified time frame and sustained financial losses might be eligible for compensation as part of the class action.

Lead Plaintiff Implications

Being appointed as a lead plaintiff can have significant implications. Lead plaintiffs tend to be investors with the largest verified losses, positioning them to oversee the legal process actively. They inspire greater scrutiny over litigation strategies and settlement decisions.

Legal Strategy and Obligations

It's crucial for fiduciaries and institutional investors to manage their stock portfolios meticulously. Those with substantial losses are usually better positioned for lead plaintiff designation. Furthermore, stakeholders are encouraged to maintain comprehensive documentation related to their investments to assess potential claims effectively.

Next Steps for Investors

Affected shareholders should consider gathering their brokerage records demonstrating purchase dates, quantities, and prices paid. Levi & Korsinsky recommends submitting this information for a no-cost evaluation of eligibility for recovery. Notably, selling shares during the class period does not preclude eligibility; affected investors can still participate based on their purchase records.

Frequently Asked Questions

To clarify the ongoing litigation's complexities, here are some frequently asked questions associated with the lawsuit:
1. Who is eligible to join the AARD class action?
Investors who purchased shares during the class period and experienced financial losses may qualify for participation.
2. When was the class action filed?
The case was filed in the Southern District of California under the Private Securities Litigation Reform Act of 1995.
3. What happens for those who already sold their AARD shares?
Even investors who sold their shares are potentially eligible for recovery if they bought during the established period.

Conclusion

As the October deadline approaches, institutional investors in Aardvark Therapeutics must stay informed about their rights and opportunities regarding this class action lawsuit. Legal counsel from firms like Levi & Korsinsky can provide essential support in navigating these complex waters. Interested parties are encouraged to take action promptly to protect their interests and explore potential recovery options.